MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy.
Adult
Animals
Cell Culture Techniques
/ methods
Cell Line
Cell Line, Tumor
Female
Humans
Lactoferrin
/ pharmacology
Lymphatic Metastasis
Melanoma
/ drug therapy
Mice
Mice, Inbred NOD
Pregnancy
Primary Cell Culture
Proto-Oncogene Proteins B-raf
/ genetics
Skin Neoplasms
/ pathology
Xenograft Model Antitumor Assays
/ methods
anti-tumor peptides
in vitro model
melanoma
pregnancy
tumor heterogeneity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Oct 2021
20 Oct 2021
Historique:
received:
30
08
2021
revised:
12
10
2021
accepted:
13
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Melanomas are aggressive tumors with a high metastatic potential and an increasing incidence rate. They are known for their heterogeneity and propensity to easily develop therapy-resistance. Nowadays they are one of the most common cancers diagnosed during pregnancy. Due to the difficulty in balancing maternal needs and foetal safety, melanoma is challenging to treat. The aim of this study was to provide a potential model system for the study of melanoma in pregnancy and to illustrate melanoma heterogeneity. For this purpose, a pigmented and a non-pigmented section of a lymph node metastasis from a pregnant patient were cultured under different conditions and characterized in detail. All four culture conditions exhibited different phenotypic, genotypic as well as tumorigenic properties, and resulted in four newly established melanoma cell lines. To address treatment issues, especially in pregnant patients, the effect of synthetic human lactoferricin-derived peptides was tested successfully. These new
Identifiants
pubmed: 34768746
pii: ijms222111318
doi: 10.3390/ijms222111318
pmc: PMC8583216
pii:
doi:
Substances chimiques
lactoferricin B
146897-68-9
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Lactoferrin
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Br J Dermatol. 2017 Oct;177(4):936-944
pubmed: 28278349
Cell Mol Life Sci. 2005 Apr;62(7-8):784-90
pubmed: 15868403
Clin Cancer Res. 2003 Dec 15;9(17):6483-8
pubmed: 14695152
Handb Exp Pharmacol. 2018;249:91-108
pubmed: 28275910
Cancer Cell. 2010 Nov 16;18(5):510-23
pubmed: 21075313
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Br J Cancer. 1999 Mar;79(7-8):1025-31
pubmed: 10098731
NPJ Genom Med. 2017;2:
pubmed: 28819565
Melanoma Res. 2019 Aug;29(4):446-447
pubmed: 31246727
Oncologist. 2002;7(4):279-87
pubmed: 12185292
Arch Med Sci. 2017 Oct;13(6):1493-1503
pubmed: 29181082
Ann Transl Med. 2016 Jun;4(12):237
pubmed: 27429963
Transfusion. 2007 Aug;47(8):1436-46
pubmed: 17655588
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Chem Phys Lipids. 2011 Nov;164(8):766-81
pubmed: 21945565
Adv Pharmacol. 2012;65:335-59
pubmed: 22959031
Biochim Biophys Acta Biomembr. 2020 Aug 1;1862(8):183264
pubmed: 32151609
Sci Rep. 2019 May 22;9(1):7696
pubmed: 31118427
World J Oncol. 2019 Feb;10(1):28-34
pubmed: 30834049
PLoS One. 2014 Nov 13;9(11):e111153
pubmed: 25393105
Biochim Biophys Acta. 2015 Nov;1848(11 Pt A):2918-31
pubmed: 26239537
Oncologist. 2020 Aug;25(8):e1209-e1220
pubmed: 32271498
J Transl Med. 2015 Nov 10;13:354
pubmed: 26554451
Cancer Treat Res. 2016;167:1-15
pubmed: 26601857
Nat Med. 2016 Jan;22(1):105-13
pubmed: 26618723
J Leukoc Biol. 2013 Jul;94(1):41-53
pubmed: 23667165
J Biol Chem. 2003 Mar 14;278(11):9790-5
pubmed: 12514183
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000
pubmed: 26286987
Sci Rep. 2019 Mar 11;9(1):4096
pubmed: 30858407
Biochim Biophys Acta. 2011 Nov;1808(11):2638-45
pubmed: 21810406
Front Mol Biosci. 2020 Jun 30;7:113
pubmed: 32695793
J Cell Biol. 2004 Jun 21;165(6):881-91
pubmed: 15210734
Clin Obstet Gynecol. 2015 Mar;58(1):119-24
pubmed: 25517755
Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):109-12
pubmed: 25356946
Genome Med. 2013 Apr 05;5(4):30
pubmed: 23561577
PLoS One. 2014 May 05;9(5):e92596
pubmed: 24799129
J Vis Exp. 2009 Oct 30;(32):
pubmed: 19881465
Clin Obstet Gynecol. 2011 Dec;54(4):537-45
pubmed: 22031244
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
Cancer Res. 2016 Aug 15;76(16):4765-74
pubmed: 27216186
Melanoma Res. 2017 Aug;27(4):289-299
pubmed: 28430756
J Biol Chem. 2001 Jun 1;276(22):18786-94
pubmed: 11278606
J Invest Dermatol. 2002 Jun;118(6):915-22
pubmed: 12060384
Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):172-7
pubmed: 24710085
Oncotarget. 2017 May 11;8(42):71817-71832
pubmed: 29069749
J Womens Health (Larchmt). 2019 Feb;28(2):250-257
pubmed: 30307780
PLoS One. 2019 Jan 25;14(1):e0211187
pubmed: 30682171
Transl Oncol. 2017 Dec;10(6):956-975
pubmed: 29078205
Sci Rep. 2019 Jun 26;9(1):9280
pubmed: 31243305